Antitumor efficacy of argon-helium cryoablation-generated dendritic cell vaccine in glioma

Neuroreport. 2014 Mar 5;25(4):199-204. doi: 10.1097/WNR.0000000000000045.

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells that play a critical role in priming tumor immune responses. We investigated the mechanisms of antitumor efficacy of DCs pulsed with argon-helium-cryotreated glioma cells. There was significant upregulation of maturation markers (CD80, CD86, MHC-I, and MHC-II) in argon-helium freeze-thawed lysate-pulsed DCs. The concentration of interleukin-6 (IL-6), IL-1β, tumor necrosis factor-α, and IL-12 secreted by lysate-pulsed DCs was increased. The concentration of interferon-γ secreted by T cells stimulated by lysate-pulsed DCs was increased. The cytotoxicity assay showed that T cells stimulated by lysate-pulsed DCs could kill glioma cells significantly more effectively. Our results suggest that argon-helium freeze-thawed lysate-pulsed DCs in vitro can promote DC maturation and enhance DC antigen-presenting function, and induce cytotoxic T lymphocytes to kill tumor cells. Therefore, the combination of argon-helium cryoablation and DC vaccine may represent a novel treatment method for glioma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Argon
  • Cancer Vaccines / therapeutic use*
  • Cell Death
  • Cell Line, Tumor
  • Combined Modality Therapy
  • Cryosurgery
  • Cytokines / metabolism
  • Cytotoxicity, Immunologic
  • Dendritic Cells / immunology*
  • Female
  • Glioma / immunology
  • Glioma / therapy*
  • Helium
  • Lymphocyte Activation
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • T-Lymphocytes, Cytotoxic / immunology*

Substances

  • Cancer Vaccines
  • Cytokines
  • Helium
  • Argon